Page 8 - Score Net News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Search jobs Takeda Completes Sale of Four Diabetes Products in Japan to Teijin Pharma Limited Osaka, Japan, April 1, 2021 - Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has completed the asset transfer associated with a portfolio of select non-core products in Japan to Teijin Pharma Limited (“Teijin Pharma”) for JPY 133.0 billion ®, Liovel ® and Zafatek ®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019. While the products included in the asset transfer continue to play important roles in meeting patient needs in the country, they were outside of Takeda’s chosen business areas – Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies, Oncology, and Neuroscience – core to its global long-term growth strategy. The transaction continues Takeda’s strong momentum toward optimizing its portfolio for growth by discovering and delivering life-tran

Teijin pharmaTakeda pharmaceutical company limitedJapan to teijin pharma limitedTeijin pharma limitedRare diseasesPlasma derived therapiesFiscal yearReported profitNet profitCore operating profitScore netFull year consolidated financialsடாகேடா மருந்து நிறுவனம் வரையறுக்கப்பட்டவைரேர் நோய்கள்நிதி ஆண்டுநிகர ப்ராஃபிட்